These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22998609)

  • 1. Enteric-coated mycophenolate sodium in psoriasis vulgaris: an open pilot study.
    Fallah Arani S; Waalboer Spuij R; Nijsten T; Neumann HA; Thio B
    J Dermatolog Treat; 2014 Feb; 25(1):46-9. PubMed ID: 22998609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
    Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
    Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
    Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients.
    Geilen CC; Arnold M; Orfanos CE
    Br J Dermatol; 2001 Mar; 144(3):583-6. PubMed ID: 11260019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).
    Budde K; Knoll G; Curtis J; Chan L; Pohanka E; Gentil M; Seifu Y; Marrast AC; Neumayer HH;
    Clin Nephrol; 2006 Aug; 66(2):103-11. PubMed ID: 16939066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil (CellCept) for psoriasis: a two-center, prospective, open-label clinical trial.
    Zhou Y; Rosenthal D; Dutz J; Ho V
    J Cutan Med Surg; 2003; 7(3):193-7. PubMed ID: 12704533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
    Darji P; Vijayaraghavan R; Thiagarajan CM; Sharma RK; Subbarao B; Pishardy R; Dakshinamurthy KV; Vijaykumar R; Abraham G; Bhaskar S; Agarwal L; Shah B; Abraham A; John M; Sampathkumar K; Das T; Umesh L; Sundar S; Ballal H; Jasuja S; Saxena S; Saha TK
    Transplant Proc; 2008 Sep; 40(7):2262-7. PubMed ID: 18790208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First experience with enteric-coated mycophenolate sodium (Myfortic) in severe recalcitrant adult atopic dermatitis: an open label study.
    van Velsen SG; Haeck IM; Bruijnzeel-Koomen CA; de Bruin-Weller MS
    Br J Dermatol; 2009 Mar; 160(3):687-91. PubMed ID: 19120337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study.
    Kobashigawa JA; Renlund DG; Gerosa G; Almenar L; Eisen HJ; Keogh AM; Lehmkuhl HB; Livi U; Ross H; Segovia J; Yonan N;
    J Heart Lung Transplant; 2006 Aug; 25(8):935-41. PubMed ID: 16890114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
    Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of enteric-coated mycophenolate sodium in patients with de novo and maintenance renal transplantation.
    Qin Y; Zhang F; Shen B; Liu Y; Qiu J; Guo Y; Fan Y
    Int J Clin Pract Suppl; 2014 Apr; (181):17-22. PubMed ID: 24673715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
    Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
    Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study.
    Budde K; Knoll G; Curtis J; Kahana L; Pohanka E; Seifu Y; Neumayer HH
    Transplant Proc; 2005 Mar; 37(2):912-5. PubMed ID: 15848573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study.
    Abbud-Filho M; Girón F; Hernández E; Juarez F; Liendo C; Novoa P; Toledo M;
    Transplant Proc; 2004; 36(6):1647-9. PubMed ID: 15350440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of tolerance and safety of conversion from mycophenolate mofetil to enteric-coated mycophenolic acid in renal transplant recipients.
    Qiao LW; Qu QS; Jiang X
    J Biol Regul Homeost Agents; 2017; 31(1):141-146. PubMed ID: 28337883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil.
    Doria C; Ramirez CB; Frank AM; Vaccino S; Fraser N; Marino IR
    Clin Transplant; 2009; 23(6):882-6. PubMed ID: 19573090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
    Nashan B; Suwelack B; Ivens K; Arns W; Lhotta K; Bourbigot B; Budde K; Fischer W; Pietruck F;
    Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enteric-coated mycophenolate sodium as a corticosteroid-sparing agent for the treatment of autoimmune scleritis.
    Hwang YS; Chen HC; Chen KJ; Lai CC; Yeung L; Yang KJ; Lin KK; Hsiao CH
    Cornea; 2011 Mar; 30(3):260-4. PubMed ID: 21099416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin.
    Pedraz J; Daudén E; Delgado-Jiménez Y; García-Río I; García-Díez A
    J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):702-6. PubMed ID: 16836499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients.
    Salvadori M; Holzer H; Civati G; Sollinger H; Lien B; Tomlanovich S; Bertoni E; Seifu Y; Marrast AC;
    Clin Nephrol; 2006 Aug; 66(2):112-9. PubMed ID: 16939067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.